• The Korean Society of Law and Medicine
• /
• v.18 no.1
• /
• pp.37-60
• /
• 2017

Ownership is the bundle of rights that allow a person or institute to use and control an object. As the biomedical science is advanced, we should consider whether human biological material should be recognized as property. Whether separated parts of the human body can be objects of ownership is a different issue. Many thought that separated parts of the human body could not be objects of ownership. This idea is primarily based on this thought: even if a piece of human biological material is separated from a person, it still relates to that person, and if treated as a thing, human dignity may be harmed. However, some commentators have admitted separated parts of the human body into the realm of property. Though a person owns his/her body or body parts, this does not mean that he/she can do anything he/she desires. There are many natural and social limitations to exercise the ownership of human biological material as discussed above. Human dignity is the core consideration whether or not we recognize that ownership of human biological material biomedical research and knowledge.

• Journal of Adhesion and Interface
• /
• v.9 no.4
• /
• pp.34-42
• /
• 2008

잠재적인 생체의료용 소재로서 홍합접착단백질은 그 동안 커다란 관심을 받아왔었다. 홍합접착단백질은 환경친화적인 수중접착제로써 강하면서도 유연하게 다양한 물질들의 표면에 접착하며 수분에 강하고 인체에 무해하며 생분해되는 특성을 가지고 있다. 여러 가지의 홍합접착단백질들이 홍합으로부터 발견되어 그 특성들이 연구되었으며 홍합의 접착기작에 대한 생화학적 지식들이 축적되어 왔다. 또한 이렇게 가능성이 높은 해양홍합유래의 바이오-접착소재를 현실화하려는 많은 노력들이 시도되어 왔다. 본 고에서는 홍합접착단백질의 기능적 생산에 초점을 맞추어 다양한 개발 접근방법들의 진행들의 추이를 정리하였다.

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2021.04a
• /
• pp.12-12
• /
• 2021

최근 길어진 여름 및 이상고온 현상이 지속됨에 따라 심화되는 광노화 피부의 특징으로는 건조, 굵고 깊은 주름, 탄력저하 및 불균일한 색소침착 등이 나타나게 됨. 화장품 소재는 기존 광노화 관련 화학물질인 Retinol 등을 대체하기 위해 자연 유래 성분을 적용한 신소재 연구를 진행하고 있음. 흰목이버섯(Tremella fuciformis)은 흰목이목에 속하는 버섯류로 자실체는 한천질로서, 주름이 되어 갈라져 있거나 또는 귓불 모양을 이루고 있으며, 크기는 10 cm 정도이다. 중국에서는 보양식의 주재료로 쓰일 만큼 탁월한 항노화 효능이 알려져 있다. 본 연구에서는 흰목이버섯의 자실체에서 추출하여 정제한 β-Glucan의 성분 확인, in vitro 수준의 피부 항노화 효과, 동물대체 독성 시험을 통한 피부독성 확인 및 인체 피부유효성 평가를 통한 항노화 효과를 확인하였다. 흰목이에서 추출, 정제 후 Bio-LC를 통한 유리당 분석 결과 Mannose, Fucose, Glucose를 확인하였으며, Human Keratinocyte에 UVB를 조사하여 광노화를 유발한 피부세포에 피부 자극 및 탄력저하 인자인 IL-6, TNFa 및 MMP-1을 평가한 결과 농도 의존적으로 현저히 개선됨을 확인하였다. 또한 보습 및 피부장벽 개선 인자인 Filaggrin과 Involucrin 생성효능을 평가한 결과 매우 높이 생성됨을 확인하였다. 본 연구결과를 토대로 광독성, 피부감작성 및 안점막 동물대체 독성시험을 실시한 결과 무독성임을 확인하여 피부에 안전하면서 효능이 우수한 것을 in vitro 수준에서 확인하였고, 피부 홍반완화, 주름개선, 탄력개선 및 보습증가 등 광노화 예방효과를 인체를 대상으로 평가한 결과 유의적인 홍반완화, 주름개선, 탄력 및 보습증가효과를 확인하였다. 본 연구결과를 종합하여 볼 때 흰목이버섯에서 추출, 정제한 β-Glucan은 in vitro 수준에서 자외선으로 인한 피부 트러블 완화, 탄력 및 보습개선을 확인하였고 독성시험을 통해 무자극임을 판정하였으며, 인체유효성 평가를 통해 광노화 예방효과를 확인하였으며 본 결과를 통해 아시아 및 글로벌 시장으로 천연유래 항노화 소재로 확장하고자 한다.

• Environmental Mutagens and Carcinogens
• /
• v.11 no.2
• /
• pp.148-160
• /
• 1991

Localization of isoenzyme of glutathione transferase Pi class was compared in different human tissues by immunohistochemical analysis. Strong enrich-ment of GST-Pi in the epithelial tissues was observed in the granular layer of skin, nipple and esophagus which are vulnerable to exogenous chemicals and in the duct epithelium such as pancreatic, biliary, salibvary, renal tubules as well as in the steroid biosynthesis organs such as theca and granulosa of ovary, leydig cell of testis and zona reticularis of adrenal glands.

• Journal of Life Science
• /
• v.20 no.2
• /
• pp.269-274
• /
• 2010

An antifungal antibiotic-producing strain, BCNU 2003, was isolated from forest soil in Korea. The morphological and physiological characters, and 16S rRNA sequences analysis of strain BCNU 2003 identified this strain as Bacillus genus. The Bacillus sp. BCNU 2003 showed strong antifungal activities against Aspergillus niger, Trichophyton mentagrophytes and Trichophyton rubrum with inhibition ranging from 62.05 to 63.49% by using dual culture technique. Bacillus sp. BCNU 2003 produced a maximum level of antifungal substances under aerobic incubation at 28oC and pH 6.5-7.2 for 6 days in LB broth. Ethyl acetate extract of the cultured broth showed strong antifungal activity and a broad antifungal spectrum against various pathogenic fungi. The minimum inhibitory concentration (MIC) values for its active extracts ranged between 0.0625 mg/ml and 1 mg/ml. In addition, Bacillus sp. BCNU 2003 was determined to have the ability to produce enzymes such as amylase, protease, gelatinase and catalase.

• Journal of Life Science
• /
• v.17 no.9 s.89
• /
• pp.1232-1236
• /
• 2007

Growth and DNA synthesis inhibitory effects of extracts from root bark of Ulmus parvifolia on MG-63 human osteosarcoma cells, HT-29 human colon cancer cells and K-562 leukemia cancer cells were studied. The root bark extract of Ulmus parvifolia was extracted with methanol, hot water and juice. The methanol extract showed the highest inhibitory effect on growth of MG-63, HT-29 and K-562 cancer cells by >85%. The treatment of hot water and juice extracts from root bark of Ulmus parvifolia also inhibited growth of the above cancer cells with increasing concentration. DNA synthesis of MG-63 and HT-29 cancer cells was significantly inhibited by adding methanol, hot water and juice extracts from root bark of Ulmus parvifolia with increasing concentration, showing that the inhibitory effect of growth was more effective on HT-29 cancer cells. These results suggest that the methanol extract from root bark of Ulmus parvifolia may have specific active com-pounds on anticancer effect. The hot water extract also showed a strong inhibitory effect on growth of cancer cells, indicating that the active compounds may be stable to heat.

• Microbiology and Biotechnology Letters
• /
• v.41 no.3
• /
• pp.379-382
• /
• 2013

In order to investigate the anticancer activity of an anti-yeast substance (AYS), a proteoglycan produced by Rhanella aquatilis AY2000, the cytotoxicity of the AYS against cancer cells was determined in vitro. The AYS was not cytotoxic to the human Jurkat T cell or the mouse sarcoma 180 cell, but was cytotoxic to the human colon cancer TH20 cell. The AYS was increasingly cytotoxic against human colon cancer cells in a dose-dependent manner at range from 62.5 to 500 ${\mu}g/ml$. Anticancer activity by combination of the AYS and an anticancer agent was also determined. The anticancer agent combined with the AYS was shown to possess greater synergistic anticancer activity against human colon cancer cells, as compared with the anticancer agent alone.

• Journal of the Korea Convergence Society
• /
• v.13 no.2
• /
• pp.257-262
• /
• 2022

The purpose of this study was to examine the inhibition of human cancer cell proliferation by using various concentrations of Beet Extract containing various bioactive ingredients. The six cancer cell lines used in the experiment were prostate cancer cells DU-145, lung cancer cells A549, breast cancer cells MCF-7, cervical cancer cells HeLa, liver cancer cells SNU-182, and biliary tract cancer cells SNU-1196. Human-derived cancer cell lines were used. The inhibition of cancer cell proliferation at various concentrations of Beet Extract was measured by the CCK-8 method. As a result of examining the inhibition of cancer cell proliferation, Beet Extract significantly and concentration-dependently inhibited DU145 of prostate cancer cells at all concentrations, and Lung cancer cells A549 and DU-145 of prostate cancer cells at 100ug/mL and 1000ug/mL, cervical cancer cells HeLa, and liver cancer cells SNU- 182, biliary tract cancer cell SNU-1196 showed significant proliferation inhibition at 1000ug/mL. Experiment result, the cancer cell proliferation inhibitory mechanisms of Beet Extract using various human-derived cancer cell lines can be considered to provide cancer prevention effects and the possibility of developing functional foods.

• The Korean Society of Law and Medicine
• /
• v.10 no.2
• /
• pp.455-492
• /
• 2009

(Background) Recent biotechnological breakthroughs are shedding new lights on various ethical and legal issues about human biological material. Since Rudolph Virchow, a German pathologist, had founded the medical discipline of cellular pathology, issues centering around human biological materials began to draw attention. The issues involving human biological materials were revisited with more attention along with series concerns when the human genome map was finally completed. Recently, with researches on human genes and bioengineering reaping enormous commercial values in the form of material patent, such changes require a society to reassess the present and future status of human tissue within the legal system. This in turn gave rise to a heated debate over how to protect the rights of material donors: property rule vs. no property rule. (Debate and Cases) Property rule recognizes the donors' property rights on human biological materials. Thus, donors can claim real action if there were any bleach of informed consent or a donation contract. Donors can also claim damages to the responsible party when there is an infringement of property rights. Some even uphold the concept of material patents overtaking. From the viewpoint of no property rule, human biological materials are objects separated from donors. Thus, a recipient or a third party will be held liable if there were any infringement of donor's human rights. Human biological materials should not be commercially traded and a patent based on a human biological materials research does not belong to the donor of the tissues used during the course of research. In the US, two courts, Moore v. Regents of the University of California, and Greenberg v. Miami Children's Hospital Research Institute, Inc., have already decided that research participants retain no ownership of the biological specimens they contribute to medical research. Significantly, both Moore and Greenberg cases found that the researcher had parted with all ownership rights in the tissue samples when they donated them to the institutions, even though there was no provision in the informed consent forms stating either that the participants donated their tissue or waived their rights to ownership of the tissue. These rulings were led to huge controversy over property rights on human tissues. This research supports no property rule on the ground that it can protect the human dignity and prevent humans from objectification and commercialization. Human biological materials are already parted from human bodies and should be treated differently from the engineering and researches of those materials. Donors do not retain any ownership. (Suggestions) No property rule requires a legal breakthrough in the US in terms of donors' rights protection due to the absence of punitive damages provisions. The Donor rights issue on human biological material can be addressed through prospective legislation or tax policies, price control over patent products, and wider coverage of medical insurance. (Conclusions) Amid growing awareness over commercial values of human biological materials, no property rule should be adopted in order to protect human dignity but not without revamping legal provisions. The donors' rights issue in material patents requires prospective legislation based on current uncertainties. Also should be sought are solutions in the social context and all these discussions should be based on sound medical ethics of both medical staffs and researchers.

• Korean Journal of Microbiology
• /
• v.47 no.2
• /
• pp.163-166
• /
• 2011

For reduction of side effects by anti-fungal agents, a less toxic anti-fungal substance or a synergistic substance with a new mechanism is needed. The anti-yeast substance (AYS) originated from Rahnella aquatilis strain AY2000 is like to be a heterogeneous protein. The AYS inhibited the growth of Candida albicans in culture broth, and AYS-treated cells were arrested in each phase during cell cycle. Among AYS-treated cells, the population of the cells belonging to sub-G1 phase was not increased during cell cycle. Therefore, AYS has rather yeaststatic than yeastcidal effect to C. albicans. Moreover, with combination of itraconazole or fluconazole, AYS had a synergistic anti-yeast activity against Saccharomyces cerevisiae based on the analysis of fractional inhibitory concentration index.